Read Our News And Press Releases

Read our news and press releases

As a business striving for growth, Halberd is rapidly changing. This means that we have many stories to tell, we like to share them with you.

Jul 14 2022

Halberd’s Antibody Effective Against all 4 SARS-CoV-2 Mutations, Including Omicron

By Admin|2022-07-13T20:33:40-04:00July 14th, 2022|Investor News, News, Press Releases|0 Comments

Boosts Effectiveness of Commercial Covid Antibodies by 45% Jackson Center, PA, July 14, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers developed, with appropriate protocols, a SARS-CoV-2 antibody effective against all four Covid-19 mutations currently in circulation, including Omicron. When Halberd’s antibody was combined with a leading commercially available Covid-19 antibody in an antibody cocktail, effectiveness ...

Jul 12 2022

Halberd Corporation Update, CEO Letter and 2022 Expectations

By Admin|2022-07-11T19:19:34-04:00July 12th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Q2 Accomplishments and a Look to the Future Jackson Center, PA, July 12, 2022. Halberd Corporation (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. The accomplishments for the Second Quarter ending June 30, 2022, are as follows: 2Q ACHIEVEMENTS Added an animal testing expert (DVM/PhD) ...

Jun 8 2022

Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification

By Admin|2022-06-07T21:21:57-04:00June 8th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, June 8, 2022 – Halberd Corporation (OTC-PINK: "HALB”) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the next step in obtaining FDA certification for Halberd’s patented extracorporeal disease eradication processes. Consistent with its press release of May 18, 2022, Halberd commenced its pursuits with mdi ...

May 18 2022

Halberd Engages Professional Firm to Proceed with FDA Filings

By Admin|2022-05-17T18:30:32-04:00May 18th, 2022|Investor News, News, Press Releases|1 Comment

Jackson Center, PA, May 18, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has engaged the services of mdi Consultants, Inc. (mdi) to assist Halberd in navigating the U.S. Food and Drug Administration’s (FDA) complex application and certification processes. mdi will guide Halberd on the FDA application and testing protocol and assist in filing the appropriate documents ...

May 12 2022

Halberd Submits Audited Financials; Files Form-10 as First Step to Up-list to OTCQB

By Admin|2022-05-11T18:58:14-04:00May 12th, 2022|Investor News, News, Press Releases|0 Comments

Jackson Center, PA, May 12, 2022 – Halberd Corporation (OTC-PINK: "HALB”) submitted its fully audited financials through its fiscal second quarter and Form-10 to the SEC as its initial step to up-list from OTC-PINK to OTCQB on the OTC Markets exchange. Once Halberd’s shares are qualified under the Securities Exchange Act of 1934 (the “34 ...

Apr 25 2022

Halberd CEO Letter

By Admin|2022-04-24T18:20:33-04:00April 25th, 2022|Featured, Investor News, News, Press Releases, Update Letter|0 Comments

Q1 Accomplishments and Q2 Plans Jackson Center, PA, April 25, 2022 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. Q1 OVERVIEW AND ACHIEVEMENTS Halberd demonstrated elimination of the final two of the “Top Ten” antigens linked ...

Apr 18 2022

Halberd Eliminates E. coli in 20 Minutes vs. 7-10 Days with Conventional Antibiotics

By Admin|2022-04-17T19:16:30-04:00April 18th, 2022|Featured, Investor News, Medical, Press Releases|0 Comments

Jackson Center, PA, April 18, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease states. The latest success was again extracorporeal elimination of E. coli bacteria from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro, in under 20 minutes. This ...

Apr 11 2022

Halberd Entering the Medical Metaverse(TM)

By Admin|2022-04-10T18:42:06-04:00April 11th, 2022|Investor News, News, Press Releases|0 Comments

Jackson Center, PA, April 11, 2022 – Halberd Corporation (OTC PINK:HALB) announces plans to enter the Metaverse by the creation of nonfungible tokens (NFT’s) to monetize certain intellectual properties of the company including but not limited to patents, patents pending, trade secrets, etc. Halberd is currently in negotiations to engage a team of experts in ...

Apr 4 2022

Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression

By Halberd|2022-04-05T20:32:09-04:00April 4th, 2022|Investor News, Medical, News, Press Releases|Comments Off on Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression

Jackson Center, PA, April 4, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro. Halberd, encouraged by its recent success in eliminating all ten of the top antigens associated with PTSD (Post Traumatic Stress Disorder), CTE (Chronic Traumatic ...

Mar 16 2022

Infectious Disease Specialist Will Guide Halberd’s Extracorporeal Elimination of Disease Antigens in Animals and Then Humans

By Admin|2022-03-15T22:01:14-04:00March 16th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, March 16, 2022 – Halberd Corporation (OTC-PINK: "HALB") announces its entry into the next stage of research. To guide it, having successfully eliminated the Top 10 Target Antigens associated with neurodegenerative diseases in vitro, Halberd is pleased to announce the addition of Ravi Venkata Durvasula, M.D., a renowned infectious disease specialist and ...

Previous 456 Next